Immuno-oncology
Conference Coverage
Study gives new insight into timing of combo treatment in metastatic NSCLC
Best outcomes came when immunotherapy followed radiotherapy by 1-12 months.
News
Thoracic cancer approvals differ at FDA, EMA
The EMA had fewer approvals and took longer to make decisions.
Article
Close to Me: CBOC Infusion Program
Conference Coverage
Acetaminophen linked to diminished response to immunotherapy in cancer
“Commonly used medications may have a larger impact on the efficacy and toxicity of immune checkpoint blockade than historically seen with...
News
Call for Immuno-oncology and Immunotherapy Manuscripts
News
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
Pembrolizumab plus chemo boosts pCR rate in TNBC
SAN ANTONIO – The immune checkpoint inhibitor added to standard chemotherapy increased the likelihood of a pathologic complete remission,...